In July 2018, Boston Scientific acquired the rest of 65% stake in Cryterion Medical Inc. for $202 million in cash. The acquisition has made Boston Scientific, the first company to have both ...

In July 2018, Boston Scientific acquired the rest of 65% stake in Cryterion Medical Inc. for $202 million in cash. The acquisition has made Boston Scientific, the first company to have both ...

The deal follows on from Boston Scientific’s acquisition of Cryterion Medical, where the company aims to further its atrial fibrillation ablation therapy offerings by utilising its ground-breaking ...

DUBLIN, Feb. 25, 2020 /PRNewswire/ -- The "Catheters - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. This report reviews, analyzes and projects the global ...

LONDON, Jan. 29, 2020 /PRNewswire/ -- In 2018, the urology devices market was estimated at $6.9bn and is expected to grow at a CAGR of 6.1% from 2018 to 2029. The urinary incontinence market ...

Other important tuck-in acquisitions of 2018 are Cryterion, nVision, and Securus. Cerner’s long-term earnings growth rate is expected to be 13.5%. Penumbra’s long-term earnings growth rate is ...

Notably, the company’s two single shot platforms, Cryterion and Apama, are on track to be launched in Europe by this year end and begin enrollment in IDEs for the U.S. approval. Boston ...

We have a multi-electrode RF balloon, where we'll be submitting that CE mark here in 2019, and we have a cryoballoon via our relationship with Cryterion and our purchase of them. So I think that's ...

Last year, Boston Scientific worked to build out its own cardiac ablation offerings by picking up cryoballoon device firm Cryterion for $202 million upfront and adding its products alongside its ...

Atrial fibrillation (AF), a common heart rhythm disorder, is often treated with cardiac ablation. Cardiac ablation uses RF (heating) or cryothermal (cooling) energy to scar the areas of the heart ...